Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN 株式レポート

時価総額:US$5.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Cyclerion Therapeutics マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間no data
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間3.5yrs

経営陣の近況

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO(最高経営責任者

Cyclerion Therapeutics CEOがいない、あるいは彼らに関するデータがない。


取締役

名称ポジション在職期間報酬所有権
Terrance McGuire
Independent Director5.3yrsUS$27.60k0.24%
$ 13.6k
Peter Hecht
Director5.3yrsUS$169.80k15.1%
$ 868.0k
Errol De Souza
Independent Chairman3.3yrsUS$131.08k2%
$ 115.0k
Steven Hyman
Independent Director2yrsUS$57.30k0.80%
$ 46.0k
Michael Higgins
Independent Directorless than a yearUS$43.60k0.80%
$ 46.0k
Robert Malenka
Member of Scientific Advisory Board3.5yrsデータなしデータなし
Daniela Salvemini
Member of Scientific Advisory Board3.5yrsデータなしデータなし
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78kデータなし
Andrew Budson
Member of Clinical Advisory Board3.5yrsデータなしデータなし
Eric Smith
Member of Clinical Advisory Board3.5yrsデータなしデータなし
M Westover
Member of Clinical Advisory Board3.5yrsデータなしデータなし
David Salat
Member of Clinical Advisory Board3.5yrsデータなしデータなし

3.5yrs

平均在職期間

68.5yo

平均年齢

経験豊富なボード: CYCNの 取締役会経験豊富 であると考えられます ( 3.4年の平均在任期間)。